In our latest paper, we demonstrate the importance of reducing and controlling the level of intermediate (partially-full) and empty capsids. Both impurities can impact product efficacy due to competition with fully packaged AAVs for cellular transduction and have potential implications for patient safety due to increased capsid load during dosing. Improved vector quality can be achieved through optimising vector design and bioreactor processes to reduce the biosynthetic generation of intermediate AAV capsids, whilst purification processes can be improved to reduce empty capsids. At OXB, we have been able to achieve >90% full capsids with our novel dual-plasmid system, across a range of AAV serotypes and genes of interest, up to 2,000L scale. Learn more about our inAAVate™ platform at www.oxb.com #Innovation #AAV #CDMO #Publication #ViralVectors #CellAndGeneTherapy
Oxford Biomedica
Pharmaceutical Manufacturing
Oxford, Oxfordshire 34,951 followers
A quality and innovation-led viral vector CDMO
About us
Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
- Website
-
http://www.oxb.com
External link for Oxford Biomedica
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Oxford, Oxfordshire
- Type
- Public Company
- Founded
- 1995
- Specialties
- Gene therapy, Immunotherapy, Viral vector GMP manufacturing, and Cell and gene therapy
Locations
Employees at Oxford Biomedica
Updates
-
Discover our AAV offering – the inAAVate™ platform – Oxford Biomedica’s AAV plug-and-play platform that addresses the most common AAV manufacturing challenges. 🔹12 months from project initiation to GMP Drug Product 🔹Dual-plasmid system increases productivity and is proven in GMP 🔹In-house analytical development 🔹Optimised scalable process from 2L up to 2,000L Visit www.oxb.com to learn more.
-
-
Oxford Biomedica reposted this
Inspiring the next generation…..
Guest lecturing programs like the one at Woburn Memorial High School in Massachusetts, USA ensure students enrolled in a Medical Intervention class are learning current industry trends such as gene therapy and vector manufacturing. Patricia Daggett from our US marketing department spent time as a guest lecturer with the students this week discussing the importance of gene therapy and how viral vector manufacturing in being performed just a short distance from their school at the Oxford Biomedica US site in Bedford, MA.
-
-
Thank you to everyone who joined us for our webinar on "Viral Vector Manufacturing Success Stories: Onboarding to GMP Production" last week. If you were unable to attend and would like to learn about the customer journey at OXB, end-to-end automation of analytical assays, as well as computer-aided biology strategies to enhance the development, bioprocessing and characterization of viral vectors for gene therapies, please click the link below to listen back to the recording. https://lnkd.in/ejAgYD8Z #Webinar #CDMO #GMP #Manufacturing #CellAndGeneTherapy #ViralVectors #LentiViralVectors #AAV
-
A reminder that our webinar on "Viral Vector Manufacturing Success Stories: Onboarding to GMP Production" starts at 16:00 GMT / 11:00 EST / 17:00 CET today! Click this link to sign up: https://lnkd.in/evU8hWUW
Join our free 60-minute webinar at 16:00 GMT / 11:00 EST / 17:00 CET on Wednesday 7th February offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors. Learn about: 🔹 Cutting-edge, end-to-end automation of analytical assays. 🔹 Design of Experiments to optimize vector production. 🔹 Considerations for product comparability during process changes. 🔹 Case studies to demonstrate enhancements to viral vector production and successful process transfer to GMP operations. Sign up here or click the link below: https://lnkd.in/evU8hWUW #Webinar #CDMO #GMP #Manufacturing #CellAndGeneTherapy #ViralVectors #LentiViralVectors #AAV
This content isn’t available here
Get full access in the Linkedin app
-
Following our acquisition of ABL Europe earlier this week, we are delighted to now be able to offer our clients: 🔹Combined >50 years of viral vector process development and manufacturing expertise 🔹A footprint in France for batch release in Europe, UK and USA 🔹Strengthened expertise across Adenovirus, Lentiviruses and AAVs with new capabilities in vaccines, oncolytic viruses and immunotherapy 🔹Increased capacity in process and analytical development and early-stage manufacturing 🔹6 additional EMA approved GMP suites and 1 additional fill finish suite To learn more about our CDMO services, email partnering@oxb.com #CDMO #ViralVectors #CellAndGeneTherapy
-
Oxford Biomedica reposted this
Looking forward to connecting with existing customers and helping new customers in the viral vector / vaccine space. Please reach out to learn more about our drive to becoming the most innovation-led, quality driven pure-play CDMO on the market.
Advancing gene and cell therapies
i.snoball.it
-
Today, we are excited to announce the completion of the acquisition of ABL Europe from Institut Mérieux. This acquisition strengthens our position as a world-leading cell and gene therapy CDMO, providing us with two new sites in France and increased process and analytical development capacity. Read more here: https://lnkd.in/eFuFPxaW #CDMO #CellAndGeneTherapy #ViralVectors
Completion of Transaction
otp.investis.com
-
Join our free 60-minute webinar at 16:00 GMT / 11:00 EST / 17:00 CET on Wednesday 7th February offering an in-depth view of the customer journey from client onboarding to the successful manufacture of adeno-associated virus and lentiviral vectors. Learn about: 🔹 Cutting-edge, end-to-end automation of analytical assays. 🔹 Design of Experiments to optimize vector production. 🔹 Considerations for product comparability during process changes. 🔹 Case studies to demonstrate enhancements to viral vector production and successful process transfer to GMP operations. Sign up here or click the link below: https://lnkd.in/evU8hWUW #Webinar #CDMO #GMP #Manufacturing #CellAndGeneTherapy #ViralVectors #LentiViralVectors #AAV
This content isn’t available here
Get full access in the Linkedin app
-
If you're at Advanced Therapies Week this week, stop by booth #631 to meet our Chief Commercial Officer, Sébastien Ribault and our Business Development team! #ATW24 #CDMO #CellAndGeneTherapy #ViralVectors
Have you heard the recent news from Oxford Biomedica? Catch them at booth #631 to find out more! #ATW24 #annoucement #cellandgene